RE: Change of focus16 Nov 2021 08:17
Poidster, -
"I've said a few times that covid is a, lucrative, distraction."
True, but I'd suggest text insertion thus:
I've said a few times that covid is a, lucrative, game changing for finances, distraction.
The other day I went through the Amryt Pharma's RNS's for the last year, thinking I was going to pick out DA's comments.
Plenty of reasons why I would expect to hear from the Chief Business Officer within these, but not a word from David.
The CEO spoke up on every incidence I would expect DA to contribute.
So perhaps this is his style. - Perhaps we won't be hearing from DA as much as we thought, - he'll give the show over to Paul Eros, the Novacyt Chief Business Officer, (who also doesn't have much to say for himself), - appearing in one video only, last month.
With respect to CMV, BKV and EBV, would you say that there would be a level of difficulty in developing tests for these, and therefore the risk attached to attempting to develop a test is not insignificant?
Just my thoughts on the task at hand.